Dr. Warren Hirst
Warren Hirst is Senior Director and head of the movement disorders preclinical research efforts in Biogen’s Research organization, a role he has led since joining them in 2016. Warren is responsible for developing and driving a diverse preclinical portfolio of programs, using multiple modalities, from antibodies and antisense oligonucleotides, in collaboration in Ionis, to gene therapy and small molecules, targeting mechanisms strongly supported by human genetics and pathology, to deliver novel disease-modifying therapeutics to patients.
Warren received his Ph.D. from Imperial College, London and, after a post-doc at the same institution, he moved to industry. Warren has 23 years of pharma experience, all focused on neurodegeneration research – including Alzheimer’s disease, depression, stroke and Parkinson’s disease, and drug development, holding positions of increasing responsibility at SmithKline Beecham and GlaxoSmithKline in England, before moving to the USA to join Wyeth and then Pfizer. Warren has directly lead teams that have discovered and advanced 3 molecules into clinical trials and has been on teams that have made similar advances with 12 further molecules. Warren has published over 75 peer-reviewed scientific papers. Warren is actively engaged in the wider scientific community via collaborations with key academic partners, and his service on NINDS study sections, as an ad-hoc reviewer for multiple journals including Neuron and PNAS and as a scientific advisor for multiple foundations, including The Michael J. Fox Foundation for Parkinson’s Research, the Parkinson’s Disease Foundation and the Weston Family Foundation.
Outside of work Warren enjoys snowboarding and travel (looking forward to getting back to both of these post-Covid19).